Volume 16, Number 5—May 2010
Schistosomiasis among Recreational Users of Upper Nile River, Uganda, 2007
After recreational exposure to river water in Uganda, 12 (17%) of 69 persons had evidence of schistosome infection. Eighteen percent self-medicated with praziquantel prophylaxis immediately after exposure, which was not appropriate. Travelers to schistosomiasis-endemic areas should consult a travel medicine physician.
Schistosomiasis, a parasitic infection caused by schistosome flukes, affects 207 million persons worldwide, mostly in sub-Saharan Africa (1). Schistosomiasis has been reported among travelers (2–12); 3 outbreaks have been reported among white-water rafters on the Omo River in Ethiopia (2,7,10). During September–November 2007, the Centers for Disease Control and Prevention (CDC) received reports of schistosome infection among travelers returning from white-water rafting on the Nile River, Jinja District, Uganda. Approximately 12,000 persons raft each year in Uganda, and local rafting companies believe that exposure to fast-moving white water during rafting and kayaking presents a low risk for schistosomiasis (C. McLeay, pers. comm.).
During November 30–December 5, 2007, we enrolled a convenience sample of competitors and spectators attending the international Nile Freestyle Festival kayaking event and tourists on commercial rafting trips in Jinja District, Uganda. We administered a questionnaire to collect information about participants’ demographic characteristics, use of praziquantel (the antiparasitic drug treatment for schistosome infection), and exposure to fresh water. Three months after enrollment, we asked study participants who had had a negative or indeterminate result from a blood test for schistosome antibodies at the time of enrollment to complete an Internet-based questionnaire about freshwater exposures, health symptoms, and medical tests or treatments for schistosomiasis since enrollment.
We measured infection by collecting two 5-mL blood samples 3 months apart and testing them for evidence of schistosome antibody seroconversion. We tested for presence of schistosome-specific antibodies using an ELISA assay screening test that is 99% sensitive for Schistosoma mansoni and 90% sensitive for S. hematobium (10). We confirmed FAST-ELISA–positive samples using an S. mansoni–specific immunoblot to detect species-specific antibody. We tested all samples using an S. hematobium–specific immunoblot, which is 95% sensitive and 99% specific for each species (13). We defined a positive test result as positive results by both tests, an indeterminate result as positive by FAST-ELISA but negative by immunoblot, and a negative result as negative by both tests.
We defined study participant exposures from 2 weeks before enrollment until second sample collection by 4 activity categories: no water-contact activity, swimming/wading only, kayaking/rafting only, and swimming/wading plus kayaking/rafting. We defined schistosome antibody seroconversion in participants as either being first-test–negative and second-test–positive, or being first-test–negative and second-test–indeterminate. We compared characteristics between groups using the χ2 test for categorical data and the Mann-Whitney test for continuous variables (14). We expressed the risk for infection as the proportion of persons in each activity category who had evidence of schistosome antibody seroconversion and calculated the Mantel-Haenszel χ2 test for trend (14). We performed all analyses using SAS version 9.1 (SAS Institute, Cary, NC, USA). The CDC Institutional Review Board and the Uganda Virus Research Institute approved this study.
We enrolled 150 study participants; 2 subsequently withdrew. Thirty-five (24%) participants were not followed up because their first blood test was positive; all of these persons reported previous exposure to fresh water in schistosomiasis-endemic countries. Of the remaining 113 persons eligible for follow-up, 69 (61%) provided a second blood sample. Persons who provided only 1 blood sample were more likely to be younger (p = 0.005) and female (p = 0.03) (Table 1).
Of 69 persons followed up, 23% had fever, 13% cough, 10% skin rash, and 10% abdominal pain; 8% reported prickling skin. None reported physician-diagnosed acute schistosomiasis. Twelve (17%) of the 69 persons with 2 blood samples had evidence of seroconversion. No seroconversions were identified among the 9 persons who reported no water-contact activities. Serologic data suggested that infection occurred in 1 (13%) of 8 reporting swimming/wading only; 4 (15%) of 26, kayaking/rafting only; and 7 (27%) of 26, swimming/wading plus kayaking/rafting (Table 2).
Of 106 persons for whom data were recorded, 19 (18%) reported self-medicating with praziquantel while at the kayaking competition. Of the 12 participants with evidence of seroconversion, 6 had data recorded about self-medication, none of whom took praziquantel.
Approximately one fifth of persons with recreational exposure to water on the upper Nile River in Jinja District showed evidence of schistosome antibody seroconversion. Infection occurred among persons who reported swimming/wading only, kayaking/rafting only, and both activities, which refutes the belief that exposure to fast-moving water presents a low risk for schistosomiasis.
Exposure to schistosomes is likely to be highest in slow-moving water near riverbanks; thus, persons who go rafting may be at highest risk while putting their kayaks/rafts into and taking them out of the river. Although we were unable to estimate the risk for infection attributable to fast-moving white-water exposure alone, we did find that persons who reported swimming/wading and kayaking/rafting had the highest risk, possibly because of increased duration of exposure (4).
Eighteen percent of study participants reported self-medicating with praziquantel immediately or shortly after river water exposure. However, they would not have been protected against schistosomiasis because praziquantel acts against mature schistosome parasites and thus is most effective if taken after the parasite has developed to the adult stage, which is 4–6 weeks after infection. Local advice about using praziquantel to prevent schistosomiasis may not be appropriate; because indigenous populations have ongoing exposure, timing of treatment is not as critical. Travelers with discrete freshwater exposures in schistosomiasis-endemic countries should consult a travel medicine physician. In addition, information could be made available to pharmacies, rafting companies, and travelers about when to take praziquantel.
Our study had several limitations. The study cohort was a convenience sample, and participants might not have had equal chance of being enrolled. Use of this sample may have introduced bias, although whether any such bias would contribute to overestimation or underestimation of risk is unclear. Because schistosome antibody tests do not differentiate newly acquired infection, we excluded persons with first-test–positive results from the study follow-up. However, if these persons were more likely to have had a higher risk for infection, excluding them would have led us to underestimation risk for infection.
More than 12,000 persons take rafting trips in Uganda each year. Many travelers do not follow advice to avoid freshwater activities in schistosomiasis-endemic countries (15). Travelers should be made aware that white-water exposure presents a risk for schistosomiasis and that treatment with praziquantel should be at least 4–6 weeks after last exposure, preferably under the direction of a travel medicine physician.
Dr Morgan is an epidemiologist in the Division of Emerging Infections and Surveillance Services, National Center for Emerging and Zoonotic Infectious Diseases (proposed), CDC. His primary research interest is the global epidemiology of respiratory diseases.
We are grateful to all persons who participated in this study. This study would not have been possible without the support of Cam McLeay from Adrift Adventure Company. Milton Wetaka, Rukia Haruna, and Angela Amanu contributed to the enrollment and follow-up of study participants residing in Uganda; Robert Downing and Beryl West provided support for storing and shipping laboratory samples to CDC in Atlanta; and Sarah Kigozi-Musibala provided administrative support. Pauline Han and Kristy Mugavero assisted with following-up study participants in Canada, the United States, South Africa, Australia, and New Zealand; John Stamper, Mark Lamias, and Angela Austin created the Internet-based reporting system and online questionnaires; Melanie Moser created a study website; Jessie Toporek helped with data entry; and Robert Pinner provided institutional support. We are grateful to our colleagues from public health agencies in many countries who contacted study participants and arranged for collection of blood samples. A complete list of persons and public health agencies can be found in the Appendix Table.
- Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6:411–25.
- Centers for Disease Control and Prevention. Schistosomiasis among river rafters—Ethiopia. MMWR Morb Mortal Wkly Rep. 1983;32:585–6.
- Centers for Disease Control and Prevention. Acute schistosomiasis in U.S. travelers returning from Africa. MMWR Morb Mortal Wkly Rep. 1990;39:141–2,14 7–8.
- Cetron MS, Chitsulo L, Sullivan JJ, Pilcher J, Wilson M, Noh J, Schistosomiasis in Lake Malawi. Lancet. 1996;348:1274–8.
- Chapman PJ, Wilkinson PR, Davidson RN. Acute schistosomiasis (Katayama fever) among British air crew. BMJ. 1988;297:1101.
- Colebunders R, Verstraeten T, Van Gompel A, Van den Ende J, De Roo A, Polderman A, Acute schistosomiasis in travelers returning from Mali. J Travel Med. 1995;2:235–8.
- Istre GR, Fontaine RE, Tarr J, Hopkins RS. Acute schistosomiasis among Americans rafting the Omo River, Ethiopia. JAMA. 1984;251:508–10.
- Leshem E, Maor Y, Meltzer E, Assous M, Schwartz E. Acute schistosomiasis outbreak: clinical features and economic impact. Clin Infect Dis. 2008;47:1499–506.
- Pitkanen YT, Peltonen M, Lahdevirta J, Meri S, Evengard B, Linder E. Acute schistosomiasis mansoni in Finnish hunters visiting Africa: need for appropriate diagnostic serology. Scand J Infect Dis. 1990;22:597–600.
- Schwartz E, Kozarsky P, Wilson M, Cetron M. Schistosome infection among river rafters on Omo River, Ethiopia. J Travel Med. 2005;12:3–8.
- Trachtenberg JD, Jacobson M, Noh JC, Tsang VC, Ndoskoi J, Koster F. Schistosomiasis in expatriates in the Arusha region of Tanzania. J Travel Med. 2002;9:233–5.
- Visser LG, Polderman AM, Stuiver PC. Outbreak of schistosomiasis among travelers returning from Mali, West Africa. Clin Infect Dis. 1995;20:280–5.
- Tsang VC, Wilkins PP. Immunodiagnosis of schistosomiasis. Immunol Invest. 1997;26:175–88.
- Altman D. Practical statistics for medical research. London: Chapman & Hall/CRC; 1999.
- Centers for Disease Control and Prevention. CDC Health information for international travel, 2008 [cited 2010 Mar 24]. http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-5/schistosomiasis.aspx
Suggested citation for this article: Morgan OW, Brunette G, Kapella BK, McAuliffe I, Katongole-Mbidde E, Li W, et al. Schistosomiasis among recreational users of upper Nile River, Uganda, 2007. Emerg Infect Dis [serial on the Internet]. 2010 May [date cited]. http://wwwnc.cdc.gov/eid/article/16/5/09-1740
Comments to the Authors
Comments to the EID Editors
Please contact the EID Editors via our Contact Form.
- Page created: December 23, 2010
- Page last updated: December 23, 2010
- Page last reviewed: December 23, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)